TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00325754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Cylinder
Description: Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lightweight Cylinder
Description: Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
Study: NCT00982709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic vs. Agility Training
Description: High Intensity 4x's per week for 4 weeks with a physical therapist.
Study: NCT01334723

Intervention type: DRUG
Intervention: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy
Description: Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)

Intervention type: DRUG
Intervention: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy
Description: Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)

Intervention type: DRUG
Intervention: Non-adherent to 5ARI therapy
Description: Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)

Intervention type: DRUG
Intervention: Non-adherent to 5ARI therapy
Description: Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
Study: NCT01912144

Intervention type: OTHER
Group type: OTHER
Intervention: Coffee
Study: NCT02912026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV F901318
Description: Metabolic profile AUC 0 to infinity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral F901318
Description: Metabolic profile AUC 0 to infinity
Study: NCT04139707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caring4Dementia
Description: A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Paper
Description: The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
Study: NCT01586507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ULTRAM ER
Description: The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
Study: NCT01190995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24% Sucrose
Description: The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
Study: NCT00884806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Description: Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
Study: NCT00411411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia
Description: 200 mg t.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03038854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test GUM
Description: Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard GUM
Description: Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
Study: NCT00884806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A contact lens (ACUVUE® 2™)
Description: Commercially marketed hydrogel contact lens for daily wear use
Study: NCT02916563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System Altitude Performance
Description: Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
Study: NCT00884806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens (ACUVUE® OASYS™)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (O2 OPTIX®)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens (PureVision®)
Description: Commercially marketed silicone hydrogel contact lens for daily wear use
Study: NCT04044885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
Study: NCT01692652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warm compress only group
Study: NCT01502241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2 per day on seven out of fourteen days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy of the partial brain.
Description: 60 Gy in 30 fractions à 2 Gy.
Study: NCT00091676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FNHLId1
Description: 5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KLH + GM-CSF
Description: 5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
Study: NCT00629447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innohep
Description: The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
Study: NCT00880724

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: IBV Valve
Description: Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
Study: NCT04034732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Relapses Prevention (MBRP)
Description: Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement.
Study: NCT03038854

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cows' milk
Description: Homogenized store-bought full fat cow's milk.
Study: NCT00958932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech recognition
Description: The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
Study: NCT03765203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Natera KidneyScan
Description: Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Performance and Value Vignettes
Description: Online renal allograft simulated patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Performance and Value Vignettes
Description: Online renal allograft simulated patients
Study: NCT03003507

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Formula With Fructose
Description: Low-carbohydrate Enteral Formula With Fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Formula Without Fructose
Description: Low-carbohydrate Enteral Formula Without Fructose
Study: NCT04028466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
Study: NCT00875342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCS
Description: 1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
Study: NCT01970059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Carvedilol Sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Metoprolol Succinate
Study: NCT05204433

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04034732

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
Study: NCT05204433

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01420822

Intervention type: DRUG
Intervention: Fluticasone
Description: Collection of safety data
Study: NCT02882100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted trivalent influenza vaccine
Description: Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trivalent influenza vaccine
Description: Nursing home residents are allocated to receive standard trivalent vaccine (TIV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Description: Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Study: NCT01406015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 50 mg once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching spironolactone once daily for 6 weeks.
Study: NCT01508845

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
Study: NCT01896583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7147
Description: 300 mg, tablet, twice per day for 4 weeks oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01656070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cholecalciferol 1000000 UI (vitamin D3)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00733941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High frequency training
Description: 24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal frequence training
Description: 24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
Study: NCT00678834

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: To surgery patients, Tocopherol capsules.
Description: 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol to healthy subjects.
Description: 200 mg to take orally two times a day (400 mg a day).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: To surgery patients, Tocotrienol capsules.
Description: 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
Study: NCT04382417

Intervention type: OTHER
Intervention: Observational study
Description: Not required
Study: NCT01423734

Intervention type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center.
Study: NCT02335424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT00624754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Lactose 2 puffs b.i.d for 1 month
Study: NCT03891368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative
Description: InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technical Assistance
Description: Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
Study: NCT01141478

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiotherapy
Description: Fifteen consecutive sessions
Study: NCT00703885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 mg alprazolam
Description: 0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 mg alprazolam
Description: 1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study: NCT03816878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 pISV
Description: Administered as an intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 pISV
Description: Administered as an intramuscular (IM) injection
Study: NCT04105699

Intervention type: DEVICE
Intervention: Blood sampling
Description: Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
Study: NCT03595007

Intervention type: BEHAVIORAL
Intervention: Kids Kicking Cancer program
Description: Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.

Intervention type: BEHAVIORAL
Intervention: Kids Kicking Cancer program
Description: Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.

Intervention type: BEHAVIORAL
Intervention: Kids Kicking Cancer program
Description: Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
Study: NCT03847545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine
Description: sustained-release tablet 10 mg morning and evening.
Study: NCT00590759

Intervention type: DEVICE
Group type: OTHER
Intervention: GORE TAG® Thoracic Endoprosthesis
Description: implant
Study: NCT02802111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
Study: NCT01166191

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT01230359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride
Description: 2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tang orange powder
Description: 2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks